Algernon Pharmaceuticals Announces Green Light 30-Oct-2020:08:00:00, Algernon Pharmaceuticals Announces Green Light From Data and Safety Monitoring Board to Continue its Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
>VANCOUVER, British Columbia, Oct. 30, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, is pleased to announce that after its second meeting and review, the external Data and Safety Monitoring Board (DSMB) has once again unanimously approved the continuation of the Companys multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. The DSMB is a committee of clinical research experts, including physicians, statisticians, and patient advocates, who are monitoringthe progress of the Companys clinical trial, and are reviewing safetyand effectiveness datawhile the trial is ongoing.
Clinical studies are focussed on the issues of safety and efficacy, said Christopher J. Moreau CEO of Algernon Pharmaceuticals. We are very confident of Ifenprodils safety and we look forward to discovering its efficacy in this very important COVID-19 trial.
The Company is not making any express or implied claims that Ifenprodil has the ability to eliminate, cure or contain COVID-19 (SARS-2 Coronavirus) at this time.
Phase 2b/3 Study Protocol Summary
The Companys multinational Phase 2b/3 human trial for COVID-19 is entitled, “A Randomized Open Label Phase 2b/3 Study of theSafety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patients with Confirmed COVID-19 Disease.”
The trial is currently underway as a Phase 2b study of an aggregate of 150 patients. With positive preliminary data, the clinical trial will move directly into a Phase 3 trial. The data from the Phase 2b study will determine the number of patients needed to reach statistical significance in the Phase 3 trial.
Patients are being randomized in a one-to-one manner and are either being treated using an existing standard of care, or standard of care plus Ifenprodil 60 mg (taken as one 20 mg tablet three-times daily) for one arm or standard of care plus Ifenprodil 120 mg (taken as two 20 mg tablets three-times daily) for two weeks.
Over the testing period, doctors will observe whether there is an improvement in a number of secondary endpoints, including mortality, blood oxygen levels, time spent in intensive care and time to mechanical ventilation.